Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada

MONTREAL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) for Qelbree^® (viloxazine extended-release capsules) has been accepted for review by Health Canada. Qelbree^® is a novel nonstimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD).

Read more at globenewswire.com